Liquid biopsy
Discover our MRD (Minimal Residual Disease) detection solution - an ultrasensitive approach based on liquid biopsies.
WHAT IS THE MRD SOLUTION?
In cancer management, the detection of minimal residual disease (MRD), using a simple blood test and circulating free DNA (cfDNA) analysis, has become essential for anticipating relapse, assessing response to treatment and improving clinical outcomes in oncology.
In this Application Note, find out how IntegraGen, in collaboration with Twist Bioscience, has implemented a complete liquid biopsy solution based on high-throughput sequencing (NGS), enabling ultra-sensitive detection of ctDNA with a detection limit of up to 0,003 %.
Our workflow combines :
- Custom panels via exomic sequencing (WES) for the detection of hundreds of personalized tumor variants,
- Optimum yield library preparation using the Twist cfDNA Library Preparation and Hyb Mix Kit,
- And advanced bioinformatics analysis using UMI-based duplex sequencing for maximum specificity and error correction.
The approach has been validated on cohorts of patients with digestive cancers, demonstrating exemplary robustness and specificity.
WHY DOWNLOAD THIS NOTE APPLICATION?
- Understand the key steps in developing a tumor-informed MRD workflow.
- Discover concrete results obtained on real clinical samples.
- Draw on a robust approach for your clinical trials and MRD monitoring projects.
